Ferric Carboxymaltose [Ferinject]
Acute Coronary Syndromes (ACS)
Fundación para la Investigación del Hospital Clínico de ValenciaPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Acute Coronary Syndromes (ACS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FERRIC CATION Fundación para la Investigación del Hospital Clínico de Valencia | Phase 4 | BB |
Bempedoic Acid Punjab Institute of Cardology | Phase 4 | BB |
cg-0255 besylate Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 1 | CC |
cg-0255 besylate for Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
Ferric Carboxymaltose [Ferinject] is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →